Cingulate (CING) Registration Filing summary

Company overview and business model

• Operates as a biopharmaceutical company leveraging proprietary Precision Timed Release (PTR) technology to develop next-generation pharmaceuticals targeting conditions with burdensome daily dosing and suboptimal outcomes.

• Initial focus is on ADHD and anxiety, with two lead stimulant candidates (CTx-1301 and CTx-1302) designed for once-daily dosing and improved side effect profiles.

• PTR platform enables multi-dose tablets with pre-defined release intervals, aiming to address unmet needs in ADHD treatment and expand into other therapeutic areas with significant market potential.

• Pipeline selection criteria include potential for $1 billion+ peak annual sales and clear therapeutic differentiation.

Financial performance and metrics

• As of January 12, 2026, public float market value was $37,286,229.76, based on 7,339,809 shares at $5.08 per share.

• In the prior 12 months, $3,588,312.46 in securities were sold under Form S-3, with a cap of one-third of public float in any 12-month period if public float is under $75 million.

• The audit report for 2024 notes substantial doubt about the company's ability to continue as a going concern due to losses and negative cash flows from operations.

Use of proceeds and capital allocation

• Net proceeds will fund continued R&D and commercialization of CTx-1301, R&D for CTx-1302 and CTx-2103, working capital, capital expenditures, and general corporate purposes.

• Pending use, proceeds will be invested in short-term, interest-bearing or investment-grade securities.